Big Pharma is in war with the United Kingdom, and the government cannot retreat now Nick Dern
R.A year so far, some of the world’s largest pharmaceutical companies in the world Withdrawing about 2 billion pounds in the proposed investment From the United Kingdom. One has even threatened to block new drugs from NHS patients. Combated, it is difficult not to conclude that Big Pharma is in war with the United Kingdom.
Merk Abolish A billion pounds of research is attached, while Astrazneca abandoned a 450 million pounds vaccine laboratory and rethinking another research unit. Bristol Myers Squibb (BMS) canceled 34 partnerships with NHS last year, and it is believed that Eli Lilly, Sanofi and Novartis have placed “suspended” investments. BMS is also A threat to play football Thanks to the new schizophrenia, saying that he is “ready to make the difficult decision” with “away” if NHS does not pay the price that the company wants to impose.
One of the senior government officials told the Financial Times that companies were working together, saying that the machine’s speed of industry threats “looks very coordinated.” they Behavior description “Evil”, and they said they “have seen nothing like this before.” (The President of the British Pharmaceutical Society said that such accusation is “very dangerous” and “incorrectly incorrect”). Three organizations, including those for which I work, have requested the authority to compete and markets more.
One of the ways to understand the actions of industry is a large -scale capital strike, as international capital rejects investment for bullying in concessions. In this case, the clear disagreement point is NHS drug spending. A long time ago, the industry entered the National Institute of Health and Care (NICE), a body that allows NHS to judge the value of medicines, and in fact, negotiate prices. It is the least happier in the volunteer plan for branded pharmaceutical prices, access and growth (VPAG), which allows the government to review some of its revenues when the prices that NHS pay very quickly – a program that the industry described as “not sustainable”. In short, Big Pharma hates the power that NHS must impose outrageous prices. Each opportunity is used to retract this strength.
The last opportunity comes in the shape of Donald Trump. It is not a coincidence that Big Pharma screams hysterically at the time of time from the US President’s recent visit to the United Kingdom. Trump should be seen as dealing with water -filled drug prices in the United States, and the country where the pharmaceutical industry is really earned.
Traditionally, the United States did little to contain drug prices. Biden began facing the industry, forcing companies to negotiate prices. Trump’s solution is different – correct in writing, as he believes that the problem is not desperate companies in urgent need of organization, but foreigners deprived. Until the end of the month, pharmaceutical companies have been granted to start the global price equation. Nobody knows what will happen after that, although the customs tariff reaches 200 % Suggested.
in The tariff agreement with Trump Earlier this year, Starmer pledged to “improve the total environment of pharmaceutical companies.” Trump did not forget. In “lukewarm” A meeting with Rachel Reeves Earlier this month, the Ambassador of the billionaire in the United States prompted London with the strength of the consultant to provide companies with a better deal on drug prices.
Big Pharma uses any crisis as an opportunity to enhance its already enlarged profits. With Trump’s support, he is determined to pay his long -term goals.
It is not simply that Britain pays very little to its drugs. Last year, NHS England spent near 20 billion pounds sterling on medicines and devices. Research has repeatedly showed that the brand Medicines are actually expensiveInstead of very cheap, for the benefits they provide to patients, even with discounts and Clawbacks.
The truth is that Big Pharma is already one of the most profitable industries in the world. Transferring more NHS budgets to satisfy these wealthy international companies in a fictional way will not help patients. This week, the Minister of Science, Patrick Vallas, said that this is important The high prices were necessary To end the conflict. Wes Street, the Minister of Health, has so far stood at home, saying correctly that he had already made a generous offer. For all of our saakes, the government must stand firm.
Britain is likely to reduce its investments in medical research. But delivering empty checks to Big Pharma will not make us better medicines. Instead, we must take this opportunity to end the screws that these companies enjoy on our health care, and restructuring the way we make our medicines. This will cost the money. But the drugs cost the public a fortune anyway.
We must work with countries throughout Europe to build the ability to search on a global control in general. After that, instead of handing this research to the pharmaceutical industry, we must develop a different model that allows the participation and license of research in a way that supports international cooperation to produce better drugs for all.
After promoting the newsletter
Meanwhile, we need to build manufacturing capacity. The state does not have to produce every drug we need, but we need more general capacity so that we cannot keep it again in a ransom.
Finally, we must work with countries in the global south to help enhance their research and production capacity as well, breaking the dominance of large drugs at the international and national levels.
Large medications flourish on hegemony, bullying and exclusion. NHS was built on exactly opposite principles. Let’s take this opportunity to expand the values in which we manage our medicines the way we produce it.